CROI 2016 Program at a Glance

Program and Agenda

Session P-T5 Poster Abstracts

Hall D

Session P-V2 Poster Abstracts

Hall D

2:45 PM-4:00 PM Antiretroviral Therapy and Viral Suppression in Children: Implications for Cure 836 Strong IFN-g Responses and Limited HIV Reservoirs in Adolescent Virologic Controllers Jason Brophy 1 ; Fatima Kakkar 2 ; Hinatea Dieumegard 3 ; Amelie Pagliuzza 4 ; Ari Bitnun 5 ; Lindy Samson 1 ; Stanley Read 5 ; Nicolas Chomont 6 ; Hugo Soudeyns 7 ; for the EPIC4 Study Group 1 Children’sHospofEasternOntario,Ottawa,ON,Canada; 2 Univde Montréal,Montréal,QC,Canada; 3 CHUSainte-Justine,Montréal,QC, Canada; 4 CRCHUM,Montreal,QC,Canada; 5 Hosp forSickChildren,Univof Toronto,Toronto,ON,Canada; 6 UnivdeMontréal,Montreal,QC,Canada; 7 CHUSainte-Justine,Montreal,QC,Canada Matias Moragas ; Debora Mecikovsky; Solange Arazi Caillaud; Paula Aulicino; Rosa Bologna; Luisa Sen; Andrea Mangano HospdePediatríaSAMICProfDr JuanP.Garrahan,BuenosAires, Argentina 838 HIV-1 DNA Dynamics Over a Decade or More of Viral Suppression in Perinatal Infection Priyanka Uprety 1 ; Kunjal Patel 2 ; Brad Karalius 2 ; Kaitlin Rainwater- Lovett 1 ; Carrie Ziemniak 1 ;Ya Chen 1 ; Suzanne Siminski 3 ; Russell B.Van Dyke 4 ; George R. Seage 2 ; Deborah Persaud 1 1 JohnsHopkinsUniv,Baltimore,MD,USA; 2 HarvardSchofPH,Boston, MA,USA; 3 FrontierSci&TechRsrFndn, Inc,Amherst,NY,USA; 4 Tulane UnivSchofMed,NewOrleans,LA,USA 839 Value of Ultrasensitive HIV Assay in Infants With Negative Routine Laboratory Results Arjen J. Stam 1 ; Denise van Hout 1 ; Sibyl P. Geelen 1 ; Annelies Riezebos- Brilman 2 ; Joop Schellekens 3 ; E. H. Schölvinck 2 ; KikiTesselaar 1 ;Tom F. Wolfs 1 ; Monique Nijhuis 1 ; Anne M.Wensing 1 1 UnivMedCntrUtrecht,Utrecht,Netherlands; 2 UnivMedCntrGroningen, Groningen,Netherlands; 3 CERTE,Groningen,Netherlands 840 HIV Antibodies and Reservoir Size in Perinatally Infected Children on HAART 837 Kinetics of Cell-Associated HIV DNA During Viral Suppression in HIV-Infected Children Josephine Brice 1 ; FatoumataTiguemTelly 2 ; Maxime Grudé 3 ; Anne Derache 4 ; Deenan Pillay 4 ; Francis Barin 5 ;Vincent Calvez 3 ; Maryam Sylla 6 ; Almoustapha Maiga 7 ; Anne-Geneviève Marcelin 3 1 UMR-S1136PierreLouis InstofEpiandPH,Paris,France; 2 SEREFO, UnivofScisTechniquesandTechnologiesofBamako,Bamako,Mali; 3 SorbonneUnivs,Paris,France; 4 AfricaCntr forHlthandPopStudies, Mtubatuba,SouthAfrica; 5 François-RabelaisUniv,Tours,France, Tours,France; 6 CHUGabrielToure,Bamako,Mali; 7 SEREFO,UnivofScis TechniquesandTechnologiesofBamako,Bamako,Mali

2:45 PM-4:00 PM Topical and Systemic Preexposure Prophylaxis: New Agents, New Populations 871 Phase I Trial to Assess Safety, PK, and PD of Film and Gel Formulations of Tenofovir Katherine E. Bunge 1 ; Charlene S. Dezzutti 1 ; Craig Hendrix 2 ; Mark A. Marzinke 2 ; Hans Spiegel 3 ; Bernard Moncla 4 ; Jill Schwartz 5 ; Leslie Meyn 4 ; Lisa Rohan 1 ; Sharon L. Hillier 4 1 UnivofPittsburgh,Pittsburgh,PA,USA; 2 JohnsHopkinsUniv,Baltimore, MD,USA; 3 DAIDS,NIAID,NIH,Rockville,MD,USA; 4 Magee-Womens Hospof theUnivofPittsburghMedCntr,Pittsburgh,PA,USA; 5 CONRAD, Arlington,VA,USA 872 Safety and Pharmacokinetics of Dapivirine Vaginal Rings in Postmenopausal US Women Beatrice A. Chen 1 ; Craig Hoesley 2 ; Robert A. Salata 3 ; Jingyang Zhang 4 ; Lydia E. Soto-Torres 5 ; Annalene Nel 6 ; Sherri Johnson 7 ; Charlene S. Dezzutti 1 ; Mark A. Marzinke 8 ; for the MTN-024/IPM 031 Protocol Team for the MicrobicideTrials Network 1 UnivofPittsburgh,Pittsburgh,PA,USA; 2 UnivofAlabamaat Birmingham,Birmingham,AL,USA; 3 CaseWesternReserveUniv, Cleveland,OH,USA; 4 SCHARP,Seattle,WA,USA; 5 NIAID,NIH,Bethesda, MD,USA; 6 IntlPartnership forMicrobicides,Paarl,SouthAfrica; 7 FHI360, WashingtonDC,DC,USA; 8 JohnsHopkinsUniv,Baltimore,MD,USA 873 Adherence and Acceptability of a Dapivirine Vaginal Ring in Postmenopausal US Women Ariane van der Straten 1 ; Nicole Laborde 1 ; Helen Cheng 1 ; Craig Hoesley 2 ; Robert A. Salata 3 ; Sherri Johnson 4 ; Annalene Nel 5 ; Lydia E. Soto-Torres 6 ; Beatrice A. Chen 7 ; for the MTN-024/IPM 031 Protocol Team for the MicrobicideTrials Network 1 RTI,SanFrancisco,CA,USA; 2 UnivofAlabamaatBirmingham, Birmingham,AL,USA; 3 CaseWesternReserveUniv,Cleveland,OH,USA; 4 FHI360,WashingtonDC,DC,USA; 5 IntlPartnership forMicrobicides, Paarl,SouthAfrica; 6 NIAID,NIH,Bethesda,MD,USA; 7 UnivofPittsburgh, Pittsburgh,PA,USA 874 Distinct Pharmacodynamic Activity of Rilpivirine in Mucosal Explant Tissue Charlene S. Dezzutti 1 ; Laura J. Else 2 ; Sarah E.Yandura 3 ; Cory Shelter 3 ; Julie Russo 3 ; David J. Back 2 ; Ian McGowan 4 1 UnivofPittsburgh,Pittsburgh,PA,USA; 2 UnivofLiverpool,Liverpool,UK; 3 Magee-WomensHospof theUnivofPittsburghMedCntr,Pittsburgh,PA, USA; 4 UnivofPittsburghSchofMed,Pittsburgh,PA,USA 875 A First-in-Human Trial of PC-1005 (MIV-150 and Zinc Acetate in a Carrageenan Gel) Barbara A. Friedland 1 ; Craig Hoesley 2 ; Marlena Gehret Plagianos 1 ; Shimin Zhang 1 ; Elena Hoskin 1 ; Mohcine Alami 1 ; NataliaTeleshova 1 ; Thomas Zydowsky 1 ; José Fernández-Romero 1 ; George Creasy 1 1 PopCouncil,NewYork,NY,USA; 2 UnivofAlabamaatBirmingham, Birmingham,AL,USA 876 CVLs FromWomen Vaginally DosedWith PC-1005 Inhibit Mucosal HIV-1 and HSV-2 Ex Vivo GuillermoVillegas 1 ; Shimin Zhang 1 ; Olga Mizenina 1 ; Kyle Kleinbeck 1 ; Michael Cooney 1 ; Craig Hoesley 2 ; George Creasy 1 ; José Fernández- Romero 1 ;Thomas Zydowsky 1 ; NataliaTeleshova 1 1 PopCouncil,NewYork,NY,USA; 2 UnivofAlabamaatBirmingham, Birmingham,AL,USA

Poster Listings

98

CROI 2016